Coronary disease & ACS

Stepwise provisional versus systematic culotte for stenting of true coronary bifurcation lesions: five-year follow-up of the multicentre randomised EBC TWO Trial

EuroInterventionPublished Randomised controlled trial

Primary resultResult — go to the resultHazard ratio 0.75 95% CI 0.41–1.38

Authors' conclusion

In large non-left main true bifurcation lesions, the use of a systematic culotte strategy showed no benefit over provisional stenting for the composite outcome of all-cause mortality, myocardial infarction, or target vessel revascularisation at 5 years.

Study context

Population
Patients undergoing stenting of non-left main true bifurcation lesions (side branch diameter ≥2.5 mm, lesion length >5 mm)197 completed 5-year follow-up
Participants
200 patients
Comparison
Stepwise provisional vs systematic culotte stenting
Primary endpoint
Composite of:
  • All-cause mortality
  • MI
  • Target vessel revascularisation
Follow-up
5 years
Methodological detailsmulticentre, 5-year follow-up
  • Multicentre
  • 5-year follow-up

Primary result

As reported in the abstract

Hazard ratio

0.75

95% CI 0.41–1.38

By group

Provisional vs Systematic culotte
HR 0.75 (95% CI 0.41–1.38)

Further findings

All-cause mortality, MI, TVR (individual components) · 5 years

No significant differences: all-cause mortality 7.8% vs 7.2%, HR 1.11 (95% CI 0.40-3.05)
MI 8.7% vs 13.4%, HR 0.64 (95% CI 0.27-1.50)
TVR 6.8% vs 9.3%, HR 1.12 (95% CI 0.37-3.34)

Primary endpoint by extent of side branch disease

No significant interaction
P = 0.34

Safety

Stent thrombosis · 5 years

Similar rates: 1.9% vs 3.1%, HR 0.63 (95% CI 0.11-3.75)

Original publication

Stepwise provisional versus systematic culotte for stenting of true coronary bifurcation lesions: five-year follow-up of the multicentre randomised EBC TWO Trial. EuroIntervention. Published 16 May 2023. doi:10.4244/eij-d-23-00211

Summarised from the published abstract; every number is checked against it

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.